Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model

Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of T-cell non-Hodgkin lymphoma (NHL) mainly affecting children and young adults. About 70% of systemic ALCLs are associated with a characteristic chromosomal translocation, t(2;5)(p23;35) which fuses the anaplastic lymphoma kinas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2019-11, Vol.134 (Supplement_1), p.2542-2542
Hauptverfasser: Poggio, Teresa, Graessel, Linda, Kreutmair, Stefanie, Miething, Cornelius, Pfeifer, Dietmar, Andrieux, Geoffroy, Boerries, Melanie, Follo, Marie, Turner, Suzanne, Zeiser, Robert, Duyster, Justus, Illert, Anna Lena
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2542
container_issue Supplement_1
container_start_page 2542
container_title Blood
container_volume 134
creator Poggio, Teresa
Graessel, Linda
Kreutmair, Stefanie
Miething, Cornelius
Pfeifer, Dietmar
Andrieux, Geoffroy
Boerries, Melanie
Follo, Marie
Turner, Suzanne
Zeiser, Robert
Duyster, Justus
Illert, Anna Lena
description Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of T-cell non-Hodgkin lymphoma (NHL) mainly affecting children and young adults. About 70% of systemic ALCLs are associated with a characteristic chromosomal translocation, t(2;5)(p23;35) which fuses the anaplastic lymphoma kinase (ALK) gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5, resulting in the NPM-ALK fusion gene, its over-expression and constitutive kinase activity. Immunophenotypic characterization of human ALCL revealed highly CD30-positive cells of T- or Null-Cell-origin and resulted in promising clinical trials with CD30-coupled antibodies. However, the impact of CD30 on disease development remains unclear and the relationship between NPM-ALK and CD30 has been investigated mostly using cell line models. Syngeneic mouse models of cancer can serve as useful models since the tumors develop in situ where the contribution made by the immune system and the extracellular matrix can be investigated. Here, we focus on the involvement of CD30 in a retroviral murine bone marrow transplantation model of ALCL. In this model, the BM of Lck-Cre-transgenic mice is infected with a MSCV-Stop-NPM-ALK-IRES-EGFP vector leading to expression of NPM-ALK in early T-cells. With a latency of 3-4 months, mice develop lymphomas and die from neoplastic T-cell-infiltration of BM and lymphatic organs. To investigate the impact of abrogation of CD30 signals on the development of NPM-ALK+ ALCL in our model, CD30 knockout mice were crossed with Lck-Cre mice. Both Lck-Cre NPM-ALK CD30 wt and Lck-Cre NPM-ALK CD30 ko recipients develop a human ALCL-like lymphoma with a pure T-cell phenotype characterized by Thy1.2+ cells infiltrating the thymus, lymph nodes, spleen and BM. First results from Lck-Cre NPM-ALK CD30 ko transplanted mice showed impaired disease induction and prolonged survival compared to CD30 wt animals. Moreover, secondary transplantation of NPM-ALK thymic lymphomas led to distinct deceleration of disease development upon CD30 deletion. Microarray analyses have shed some light on the mechanisms underlying the delayed lymphoma progression of CD30 deleted tumors with an upregulation of inflammatory pathways and proteins that are master players in inflammation and immune responses. Further characterization of the role of CD30-mediated immune response in disease progression using this mouse model and immunocompromised mice is ongoing. An improved understanding of how the immune
doi_str_mv 10.1182/blood-2019-125589
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2019_125589</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497118604719</els_id><sourcerecordid>S0006497118604719</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1379-4426d0b2b6f2f8a4d3d4194b24998f2224cea292e5c9c18e3e517ac4215deff13</originalsourceid><addsrcrecordid>eNp9kMtOwzAURC0EEqXwAez8AwHfG6eNxaoK5SGCkBCsLce-bo2SuIoDon9PS1mzmVmd0egwdgniCqDE66aN0WUoQGWARVGqIzaBAstMCBTHbCKEmGVSzeGUnaX0IQTIHIsJe1p-my70oV_xcU38NbbEo-fVbS546Lnp-aI3m9akMVhem2FFvKK25fW226xjZ_hz_Ey0S0ftOTvxpk108ddT9n63fKsesvrl_rFa1JmFfK4yKXHmRIPNzKMvjXS5k6Bkg1Kp0iOitGRQIRVWWSgppwLmxkqEwpH3kE8ZHHbtEFMayOvNEDozbDUIvbehf23ovQ19sLFjbg4M7Y59BRp0soF6Sy4MZEftYviH_gEpqGYT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Poggio, Teresa ; Graessel, Linda ; Kreutmair, Stefanie ; Miething, Cornelius ; Pfeifer, Dietmar ; Andrieux, Geoffroy ; Boerries, Melanie ; Follo, Marie ; Turner, Suzanne ; Zeiser, Robert ; Duyster, Justus ; Illert, Anna Lena</creator><creatorcontrib>Poggio, Teresa ; Graessel, Linda ; Kreutmair, Stefanie ; Miething, Cornelius ; Pfeifer, Dietmar ; Andrieux, Geoffroy ; Boerries, Melanie ; Follo, Marie ; Turner, Suzanne ; Zeiser, Robert ; Duyster, Justus ; Illert, Anna Lena</creatorcontrib><description>Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of T-cell non-Hodgkin lymphoma (NHL) mainly affecting children and young adults. About 70% of systemic ALCLs are associated with a characteristic chromosomal translocation, t(2;5)(p23;35) which fuses the anaplastic lymphoma kinase (ALK) gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5, resulting in the NPM-ALK fusion gene, its over-expression and constitutive kinase activity. Immunophenotypic characterization of human ALCL revealed highly CD30-positive cells of T- or Null-Cell-origin and resulted in promising clinical trials with CD30-coupled antibodies. However, the impact of CD30 on disease development remains unclear and the relationship between NPM-ALK and CD30 has been investigated mostly using cell line models. Syngeneic mouse models of cancer can serve as useful models since the tumors develop in situ where the contribution made by the immune system and the extracellular matrix can be investigated. Here, we focus on the involvement of CD30 in a retroviral murine bone marrow transplantation model of ALCL. In this model, the BM of Lck-Cre-transgenic mice is infected with a MSCV-Stop-NPM-ALK-IRES-EGFP vector leading to expression of NPM-ALK in early T-cells. With a latency of 3-4 months, mice develop lymphomas and die from neoplastic T-cell-infiltration of BM and lymphatic organs. To investigate the impact of abrogation of CD30 signals on the development of NPM-ALK+ ALCL in our model, CD30 knockout mice were crossed with Lck-Cre mice. Both Lck-Cre NPM-ALK CD30 wt and Lck-Cre NPM-ALK CD30 ko recipients develop a human ALCL-like lymphoma with a pure T-cell phenotype characterized by Thy1.2+ cells infiltrating the thymus, lymph nodes, spleen and BM. First results from Lck-Cre NPM-ALK CD30 ko transplanted mice showed impaired disease induction and prolonged survival compared to CD30 wt animals. Moreover, secondary transplantation of NPM-ALK thymic lymphomas led to distinct deceleration of disease development upon CD30 deletion. Microarray analyses have shed some light on the mechanisms underlying the delayed lymphoma progression of CD30 deleted tumors with an upregulation of inflammatory pathways and proteins that are master players in inflammation and immune responses. Further characterization of the role of CD30-mediated immune response in disease progression using this mouse model and immunocompromised mice is ongoing. An improved understanding of how the immune system affects tumor progression will extend the rationale in translational strategies to use immunotherapies for patients with T-NHLs. No relevant conflicts of interest to declare.</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2019-125589</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2019-11, Vol.134 (Supplement_1), p.2542-2542</ispartof><rights>2019 American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Poggio, Teresa</creatorcontrib><creatorcontrib>Graessel, Linda</creatorcontrib><creatorcontrib>Kreutmair, Stefanie</creatorcontrib><creatorcontrib>Miething, Cornelius</creatorcontrib><creatorcontrib>Pfeifer, Dietmar</creatorcontrib><creatorcontrib>Andrieux, Geoffroy</creatorcontrib><creatorcontrib>Boerries, Melanie</creatorcontrib><creatorcontrib>Follo, Marie</creatorcontrib><creatorcontrib>Turner, Suzanne</creatorcontrib><creatorcontrib>Zeiser, Robert</creatorcontrib><creatorcontrib>Duyster, Justus</creatorcontrib><creatorcontrib>Illert, Anna Lena</creatorcontrib><title>Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model</title><title>Blood</title><description>Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of T-cell non-Hodgkin lymphoma (NHL) mainly affecting children and young adults. About 70% of systemic ALCLs are associated with a characteristic chromosomal translocation, t(2;5)(p23;35) which fuses the anaplastic lymphoma kinase (ALK) gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5, resulting in the NPM-ALK fusion gene, its over-expression and constitutive kinase activity. Immunophenotypic characterization of human ALCL revealed highly CD30-positive cells of T- or Null-Cell-origin and resulted in promising clinical trials with CD30-coupled antibodies. However, the impact of CD30 on disease development remains unclear and the relationship between NPM-ALK and CD30 has been investigated mostly using cell line models. Syngeneic mouse models of cancer can serve as useful models since the tumors develop in situ where the contribution made by the immune system and the extracellular matrix can be investigated. Here, we focus on the involvement of CD30 in a retroviral murine bone marrow transplantation model of ALCL. In this model, the BM of Lck-Cre-transgenic mice is infected with a MSCV-Stop-NPM-ALK-IRES-EGFP vector leading to expression of NPM-ALK in early T-cells. With a latency of 3-4 months, mice develop lymphomas and die from neoplastic T-cell-infiltration of BM and lymphatic organs. To investigate the impact of abrogation of CD30 signals on the development of NPM-ALK+ ALCL in our model, CD30 knockout mice were crossed with Lck-Cre mice. Both Lck-Cre NPM-ALK CD30 wt and Lck-Cre NPM-ALK CD30 ko recipients develop a human ALCL-like lymphoma with a pure T-cell phenotype characterized by Thy1.2+ cells infiltrating the thymus, lymph nodes, spleen and BM. First results from Lck-Cre NPM-ALK CD30 ko transplanted mice showed impaired disease induction and prolonged survival compared to CD30 wt animals. Moreover, secondary transplantation of NPM-ALK thymic lymphomas led to distinct deceleration of disease development upon CD30 deletion. Microarray analyses have shed some light on the mechanisms underlying the delayed lymphoma progression of CD30 deleted tumors with an upregulation of inflammatory pathways and proteins that are master players in inflammation and immune responses. Further characterization of the role of CD30-mediated immune response in disease progression using this mouse model and immunocompromised mice is ongoing. An improved understanding of how the immune system affects tumor progression will extend the rationale in translational strategies to use immunotherapies for patients with T-NHLs. No relevant conflicts of interest to declare.</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kMtOwzAURC0EEqXwAez8AwHfG6eNxaoK5SGCkBCsLce-bo2SuIoDon9PS1mzmVmd0egwdgniCqDE66aN0WUoQGWARVGqIzaBAstMCBTHbCKEmGVSzeGUnaX0IQTIHIsJe1p-my70oV_xcU38NbbEo-fVbS546Lnp-aI3m9akMVhem2FFvKK25fW226xjZ_hz_Ey0S0ftOTvxpk108ddT9n63fKsesvrl_rFa1JmFfK4yKXHmRIPNzKMvjXS5k6Bkg1Kp0iOitGRQIRVWWSgppwLmxkqEwpH3kE8ZHHbtEFMayOvNEDozbDUIvbehf23ovQ19sLFjbg4M7Y59BRp0soF6Sy4MZEftYviH_gEpqGYT</recordid><startdate>20191113</startdate><enddate>20191113</enddate><creator>Poggio, Teresa</creator><creator>Graessel, Linda</creator><creator>Kreutmair, Stefanie</creator><creator>Miething, Cornelius</creator><creator>Pfeifer, Dietmar</creator><creator>Andrieux, Geoffroy</creator><creator>Boerries, Melanie</creator><creator>Follo, Marie</creator><creator>Turner, Suzanne</creator><creator>Zeiser, Robert</creator><creator>Duyster, Justus</creator><creator>Illert, Anna Lena</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20191113</creationdate><title>Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model</title><author>Poggio, Teresa ; Graessel, Linda ; Kreutmair, Stefanie ; Miething, Cornelius ; Pfeifer, Dietmar ; Andrieux, Geoffroy ; Boerries, Melanie ; Follo, Marie ; Turner, Suzanne ; Zeiser, Robert ; Duyster, Justus ; Illert, Anna Lena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1379-4426d0b2b6f2f8a4d3d4194b24998f2224cea292e5c9c18e3e517ac4215deff13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Poggio, Teresa</creatorcontrib><creatorcontrib>Graessel, Linda</creatorcontrib><creatorcontrib>Kreutmair, Stefanie</creatorcontrib><creatorcontrib>Miething, Cornelius</creatorcontrib><creatorcontrib>Pfeifer, Dietmar</creatorcontrib><creatorcontrib>Andrieux, Geoffroy</creatorcontrib><creatorcontrib>Boerries, Melanie</creatorcontrib><creatorcontrib>Follo, Marie</creatorcontrib><creatorcontrib>Turner, Suzanne</creatorcontrib><creatorcontrib>Zeiser, Robert</creatorcontrib><creatorcontrib>Duyster, Justus</creatorcontrib><creatorcontrib>Illert, Anna Lena</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Poggio, Teresa</au><au>Graessel, Linda</au><au>Kreutmair, Stefanie</au><au>Miething, Cornelius</au><au>Pfeifer, Dietmar</au><au>Andrieux, Geoffroy</au><au>Boerries, Melanie</au><au>Follo, Marie</au><au>Turner, Suzanne</au><au>Zeiser, Robert</au><au>Duyster, Justus</au><au>Illert, Anna Lena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model</atitle><jtitle>Blood</jtitle><date>2019-11-13</date><risdate>2019</risdate><volume>134</volume><issue>Supplement_1</issue><spage>2542</spage><epage>2542</epage><pages>2542-2542</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Anaplastic large cell lymphoma (ALCL) represents a heterogeneous group of T-cell non-Hodgkin lymphoma (NHL) mainly affecting children and young adults. About 70% of systemic ALCLs are associated with a characteristic chromosomal translocation, t(2;5)(p23;35) which fuses the anaplastic lymphoma kinase (ALK) gene on chromosome 2 with the nucleophosmin (NPM) gene on chromosome 5, resulting in the NPM-ALK fusion gene, its over-expression and constitutive kinase activity. Immunophenotypic characterization of human ALCL revealed highly CD30-positive cells of T- or Null-Cell-origin and resulted in promising clinical trials with CD30-coupled antibodies. However, the impact of CD30 on disease development remains unclear and the relationship between NPM-ALK and CD30 has been investigated mostly using cell line models. Syngeneic mouse models of cancer can serve as useful models since the tumors develop in situ where the contribution made by the immune system and the extracellular matrix can be investigated. Here, we focus on the involvement of CD30 in a retroviral murine bone marrow transplantation model of ALCL. In this model, the BM of Lck-Cre-transgenic mice is infected with a MSCV-Stop-NPM-ALK-IRES-EGFP vector leading to expression of NPM-ALK in early T-cells. With a latency of 3-4 months, mice develop lymphomas and die from neoplastic T-cell-infiltration of BM and lymphatic organs. To investigate the impact of abrogation of CD30 signals on the development of NPM-ALK+ ALCL in our model, CD30 knockout mice were crossed with Lck-Cre mice. Both Lck-Cre NPM-ALK CD30 wt and Lck-Cre NPM-ALK CD30 ko recipients develop a human ALCL-like lymphoma with a pure T-cell phenotype characterized by Thy1.2+ cells infiltrating the thymus, lymph nodes, spleen and BM. First results from Lck-Cre NPM-ALK CD30 ko transplanted mice showed impaired disease induction and prolonged survival compared to CD30 wt animals. Moreover, secondary transplantation of NPM-ALK thymic lymphomas led to distinct deceleration of disease development upon CD30 deletion. Microarray analyses have shed some light on the mechanisms underlying the delayed lymphoma progression of CD30 deleted tumors with an upregulation of inflammatory pathways and proteins that are master players in inflammation and immune responses. Further characterization of the role of CD30-mediated immune response in disease progression using this mouse model and immunocompromised mice is ongoing. An improved understanding of how the immune system affects tumor progression will extend the rationale in translational strategies to use immunotherapies for patients with T-NHLs. No relevant conflicts of interest to declare.</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2019-125589</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2019-11, Vol.134 (Supplement_1), p.2542-2542
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2019_125589
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Examining the Role of CD30 in an Anaplastic Large Cell Lymphoma Mouse Model
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T11%3A45%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Examining%20the%20Role%20of%20CD30%20in%20an%20Anaplastic%20Large%20Cell%20Lymphoma%20Mouse%20Model&rft.jtitle=Blood&rft.au=Poggio,%20Teresa&rft.date=2019-11-13&rft.volume=134&rft.issue=Supplement_1&rft.spage=2542&rft.epage=2542&rft.pages=2542-2542&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2019-125589&rft_dat=%3Celsevier_cross%3ES0006497118604719%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497118604719&rfr_iscdi=true